For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems. Gastrointestinal Cancer Drugs are drugs that specifically treat this type of disease.
The Gastrointestinal Cancer Drugs market revenue was 2630.94 Million USD in 2022, and will reach 4585.67 Million USD in 2028, with a CAGR of 9.7% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Gastrointestinal Cancer Drugs industry, and breaks down according to the type, application, and consumption area of Gastrointestinal Cancer Drugs. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Gastrointestinal Cancer Drugs in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Gastrointestinal Cancer Drugs market covered in Chapter 11:
Celgene Corporation
Cancer Prevention Pharmaceuticals
Novartis AG
Pfizer Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Private Limited
Blueprint Medicines
GlaxoSmithKline plc.
Gastric Cancer Chemo
Sanofi
Eli Lilly and Company
In Chapter 3, on the basis of types, the Gastrointestinal Cancer Drugs market from 2018 to 2028 is primarily split into:
Immunotherapy
Chemotherapy
Targeted Therapy
Hormone Therapy
Adjuvant Chemotherapy
Radiation Therapy
Others
In Chapter 4, on the basis of applications, the Gastrointestinal Cancer Drugs market from 2018 to 2028 covers:
Hospitals
Specialized Cancer Treatment Centers
Clinics
Ambulatory Surgical Centers
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2028) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
Years considered for this report:
Historical Years: 2018-2022
Base Year: 2022
Estimated Year: 2023
Forecast Period: 2023-2028